Functional dyspepsia: Relationship between clinical subgroups and Helicobacter pylori status and Western Turkey

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 6, 2003, Pages 747-751

  Saruc, M ^a,c   Ozden, N ^c   Turkel, N ^c   Ayhan, S ^b   Demir, M A ^b   Tuzcuoglu, I ^c   Akarca, U S ^d   Yuceyar, H ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CELAL BAYAR UNIVERSITY   (Turkey)

^d EGE UNIVERSITY   (Turkey)

Author keywords

Functional dyspepsia; Helicobacter pylori; Subgroups; Symptoms

Indexed keywords

CAGA PROTEIN; GASTRIN; TUMOR NECROSIS FACTOR ALPHA; UREASE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATROPHY; CARDIA; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DYSPEPSIA; ENZYME ASSAY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; KOLMOGOROV SMIRNOV TEST; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STOMACH ANTRUM; STOMACH BIOPSY; SYMPTOMATOLOGY; TURKEY (REPUBLIC);

HELICOBACTER; HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 0038716210     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000600010     Document Type: Article

References (20)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR & Tytgat GN (1999). Functional gastroduodenal disorders. Gut, 45 (Suppl 2): II-37-II-42.
2. Laine L, Schoenfeld P & Fennerty MB (2001). Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine, 134: 361-369.
3. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A & Holtmann G (1998). AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology, 114: 582-595.
4. Talley NJ (2002). Dyspepsia: management guidelines for the millennium. Gut, 50 (Suppl 4): IV-72-IV-78.
5. Talley NJ (1997). Dyspepsia and heartburn: a clinical challenge. Alimentary Pharmacology and Therapeutics, 11 (Suppl 2): 1-8.
6. Howden CW (1997). For what conditions is there evidence-based justification for treatment of Helicobacter pylori infection? Gastroenterology, 113 (Suppl 6): S107-S112.
7. Malfertheiner P, Megraud F, C'Morain C, Hungin AP, Jones R, Axon A, Graham DY & Tytgat G (2002). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Alimentary Pharmacology and Therapeutics, 16: 167-180.
8. Hunt R & Thomson AB (1998). Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Canadian Journal of Gastroenterology, 12: 31-41.
9. Lam SK & Talley NJ (1998). Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection, Journal of Gastroenterology and Hepatology, 13: 1-12.
10. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, Kordecki H & Schmid V (1998). Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Alimentary Pharmacology and Therapeutics, 12: 1055-1065.
11. Dixon MF, Genta RM, Yardley JH & Correa P (1996). Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. American Journal of Surgical Pathology, 20: 1161-1181.
12. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K & Graham DY (1999). Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut, 45: 804-811.
13. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R & Covacci A (1996). cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proceedings of the National Academy of Sciences, USA, 93: 14648-14653.
14. Nelson DB, Murdoch M, Sandozi IK, Dalmasso AP, Crabtree JE & Ho SB (2000). Dyspepsia is associated with CagA-positive Helicobacter pylori. American Journal of Gastroenterology, 95: 3412-3417.
15. Walsh JH & Peterson WL (1995). The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. New England Journal of Medicine, 333: 984-991.
16. Holtmann G, Goebell H, Holtmann M & Talley NJ (1994). Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Digestive Diseases and Sciences, 39: 1090-1098.
17. Nandurkar S, Talley NJ, Xia H, Mitchell H, Hazel S & Jones M (1998). Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Archives of Internal Medicine, 158: 1427-1433.
18. Gilvarry J, Buckley MJ, Beattie S, Hamilton H & O'Morain CA (1997). Eradication of Helicobacter pylori affects symptoms in nonulcer dyspepsia. Scandinavian Journal of Gastroenterology, 32: 535-540.
19. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R & Hilditch T (1998). Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. New England Journal of Medicine, 339: 1869-1874.
20. Blum AL, Talley NJ, O'Morain C et al. (1998). Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. New England Journal of Medicine, 339: 1875-1881.